P

Poseida Therapeutics, Inc.

308 employees

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Transposon
Oncology
Regenerative Medicine
piggyBac® DNA Modification System
Immuno-oncology
Non-viral
Adoptive Cell Therapy
Immunology
Immunotherapy
Genetics
Cas-CLOVER™
Multiple Myeloma
T-cells
Allogeneic
Gene Therapy
CAR-T cells
Genome Engineering
Cell Therapy
Gene Editing
piggyBac®
Cytotoxic T Lymphocytes
Poseida
Therapeutics
Prostate Cancer
Biopharma
TAL-CLOVER™

Date founded

2014

Funding rounds raised

Total raised

$142M

from 14 investors over 14 rounds

P

Poseida Therapeutics, Inc. raised $110M on June 25, 2020

Investors: Adage Capital Management

P

Poseida Therapeutics, Inc. raised $142M on April 22, 2019

Investors: PENTWATER CAPITAL MANAGEMENT LP, Aisling Capital, Longitude Capital, Vivo Capital, Rapha Capital Management, LLC, Perceptive Advisors and Malin Corporation plc

P

Poseida Therapeutics, Inc. raised $31M on April 3, 2018

Investors: Malin Corporation plc, Tavistock Group, Vivo Capital and Longitude Capital

P

Poseida Therapeutics, Inc. raised $11M on August 2, 2017

Investors: Malin Corporation plc

P

Poseida Therapeutics, Inc. raised $23M on December 23, 2015

Investors: Malin Corporation plc

FAQ